The biotechnology company focuses on developing biochemical components that enhance cellular energy production and regulatory mechanisms, promoting cell restoration and regeneration in patients with respiratory and pulmonary disorders. By strengthening cellular function and reducing inflammation, the company aims to extend organ viability and improve patient outcomes.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Respiratory and pulmonary disorders, such as Cystic Fibrosis (CF), lead to impaired cellular function, chronic lung infections, breathing difficulties, and reduced quality of life due to thick mucus production and inflammation. Current treatments often fall short of fully restoring cellular health and preventing disease progression.
Solution
ODE Pharma is developing ODE-001™, a biochemical component designed to enhance cellular energy production and regulatory mechanisms, promoting cell restoration and regeneration in patients with respiratory and gastrointestinal diseases. ODE-001™ provides a required biochemical component to the cells’ powerhouses, augmenting regulatory programs to renew cells and extend organ viability. The molecule strengthens cells, reduces inflammation, and has the potential to improve the compromised quality of life for CF patients and delay disease progression. ODE-001 can be co-administered alongside existing treatments like bronchodilators, antibiotics, and gene therapy to restore CFTR proteins.
Target Audience
The primary target audience includes patients suffering from Cystic Fibrosis (CF) and other respiratory and gastrointestinal diseases, as well as healthcare providers and researchers focused on these conditions.
Features
- ODE-001™ is designed to bridge the gap from a damaged cell to an empowered cell.
- Potential to treat multiple respiratory and gastrointestinal diseases.
- Demonstrated therapeutic potential and efficacy in a Proof-of-Concept clinical trial in COVID-19.
- Comprehensive in vitro and in vivo studies on ODE-001 mechanism of action.
- Clinical trial batch of ODE-001 with three-year stability testing approval.
- Intellectual property (IP) registration has progressed to the Patent Cooperation Treaty (PCT) stage.
- Potential indications include Lung Diseases (Sepsis, ARDS, IPF, Influenza), Gut Diseases (CF Gut Implications, Inflammatory Bowel Disease, Gut Dysbiosis), and Systemic Diseases (Chronic Graft Versus Host Disease).